EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system

Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe, Ju-Yi Peng, Bernhard Sprenger, Xi He, Seyed Arad Moghadasi, Lisa Maria Egger, Jakob Fleischmann, Matteo Pavan, Davide Bassani und 17 weitere

PLOS Pathogens · 11.09.2024 · 20 (9) · e1012522

DOI: 10.1371/journal.ppat.1012522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 11.09.2024. Verfasst von Francesco Costacurta und 28 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, Medical University of Innsbruck, Innsbruck, Tyrol, Austria. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Resistance, Viral, Protease Inhibitors, Mutation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Austrian Science Fund, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2 main protease (3CL pro /M pro ) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to arise. This study aimed to identify and characterize mutations that confer resistance to nirmatrelvir. To safely generate M pro resistance mutations, we passaged a previously developed, chimeric vesicular stomatitis virus (VSV-M pro ) with increasing, yet suboptimal concentrations of nirmatrelvir. Using Wuhan-1 and Omicron M pro variants, we selected a large set of mutants. Some mutations are frequently present in GISAID, suggesting their relevance in SARS-CoV-2. The resistance phenotype of a subset of mutations was characterized against clinically available protease inhibitors (nirmatrelvir and ensitrelvir) with cell-based, biochemical and SARS-CoV-2 replicon assays. Moreover, we showed the putative molecular mechanism of resistance based on in silico molecular modelling. These findings have implications on the development of future generation M pro inhibitors, will help to understand SARS-CoV-2 protease inhibitor resistance mechanisms and show the relevance of specific mutations, thereby informing treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Drug Resistance, ViralProtease InhibitorsMutationCoronavirus 3C ProteasesAntiviral AgentsHumansCOVID-19LeucineAnimalsVesiculovirusCOVID-19 Drug TreatmentLactamsNitrilesProline

Substanzen

Protease InhibitorsCoronavirus 3C ProteasesAntiviral AgentsnirmatrelvirLeucineLactamsNitrilesProline

Autor:innen und Institutionen

  • Institute of Virology, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
  • Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padova, Italy.
  • Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Tyrol, Austria.
  • Department of Infectious Diseases and Vaccines Research, MRL, Merck & Co., Inc., Rahway, New Jersey, United States of America.
  • Institute of Biochemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
  • Department of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America.

ORCID-Profile: Emmanuel Heilmann

Förderung

  • NIAID NIH HHS
  • Austrian Science Fund
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • Merck Sharp & Dohme LLC

Zitieren

APA

Costacurta, F., Dodaro, A., Bante, D., Schöppe, H., Peng, J. Y., Sprenger, B., He, X., Moghadasi, S. A., Egger, L. M., Fleischmann, J., Pavan, M., Bassani, D., Menin, S., Rauch, S., Krismer, L., Sauerwein, A., Heberle, A., Rabensteiner, T., Ho, J., …, & Heilmann, E. (2024). A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system. PLOS Pathogens, 20(9), e1012522. https://doi.org/10.1371/journal.ppat.1012522

Vancouver

Costacurta F, Dodaro A, Bante D, Schöppe H, Peng JY, Sprenger B, et al. A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system. PLOS Pathogens. 2024;20(9):e1012522. doi:10.1371/journal.ppat.1012522

BibTeX
@article{Costacurta2024,
  author = {Costacurta, Francesco and Dodaro, Andrea and Bante, David and Schöppe, Helge and Peng, Ju-Yi and Sprenger, Bernhard and He, Xi and Moghadasi, Seyed Arad and Egger, Lisa Maria and Fleischmann, Jakob and Pavan, Matteo and Bassani, Davide and Menin, Silvia and Rauch, Stefanie and Krismer, Laura and Sauerwein, Anna and Heberle, Anne and Rabensteiner, Toni and Ho, Joses and Harris, Reuben S and Stefan, Eduard and Schneider, Rainer and Dunzendorfer-Matt, Theresia and Naschberger, Andreas and Wang, Dai and Kaserer, Teresa and Moro, Stefano and von Laer, Dorothee and Heilmann, Emmanuel},
  title = {A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system},
  journal = {PLOS Pathogens},
  year = {2024},
  volume = {20},
  number = {9},
  pages = {e1012522},
  doi = {10.1371/journal.ppat.1012522}
}
Kostenlos starten →